NYSE:PBYI

Puma Biotechnology Stock Insider Trading

Healthcare > Biotechnology

Buy PBYI

*Your capital is at risk

$8.04

+0.380 (+4.96%)

At Close: Jun 23, 2026

Puma Biotechnology Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -36.67. In total, the insiders bought 2.88M and sold 762.4K PBYI shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-36.67
● Buy	2.88M shares
● Sell	762.4K shares
43% Buy Activity Moderate Positive Correlation
Sell Signal Medium Confidence Jun 12, 2026 Analysis Breakdown: Supported by a negative Insider Power Score of -36.67. Partially supported by a positive historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 12, 2026 Sell	Common Stock S-Sale	Moyes Jay M Director	Director	22 000 Value: $158.8K
Jun 12, 2026 Sell	Common Stock S-Sale	Dorval Allison Director	Director	11 610 Value: $83.6K
Jun 12, 2026 Sell	Common Stock S-Sale	Wilson Troy Edward Director	Director	10 800 Value: $77.7K
Jun 12, 2026 Sell	Common Stock S-Sale	Stuglik Brian M Director	Director	8 100 Value: $58.3K
Jun 12, 2026 Sell	Common Stock S-Sale	Senderowicz Adrian Director	Director	27 000 Value: $194.3K
Jun 11, 2026 Buy	Common Stock A-Award	Dorval Allison Director	Director	27 000 Value: $195.2K
Jun 11, 2026 Buy	Common Stock A-Award	Moyes Jay M Director	Director	27 000 Value: $195.2K
Jun 11, 2026 Buy	Common Stock A-Award	Miller Michael Patrick Director	Director	27 000 Value: $195.2K
Jun 11, 2026 Buy	Common Stock A-Award	Wilson Troy Edward Director	Director	27 000 Value: $195.2K
Jun 11, 2026 Buy	Common Stock A-Award	Cesano Alessandra Director	Director	27 000 Value: $195.2K
Jun 11, 2026 Buy	Common Stock A-Award	Stuglik Brian M Director	Director	27 000 Value: $195.2K
Jun 11, 2026 Buy	Common Stock A-Award	Senderowicz Adrian Director	Director	27 000 Value: $195.2K
Feb 18, 2026 Buy	Stock Option (Right to Buy) A-Award	Nougues Maximo F Chief Financial Officer	C-Suite Officer	66 541 Value: $444.5K
Feb 18, 2026 Buy	Stock Option (Right to Buy) A-Award	Hunt Douglas M See Remarks	Officer	70 321 Value: $469.7K
Feb 18, 2026 Buy	Common Stock A-Award	Hunt Douglas M See Remarks	Officer	49 394 Value: $330.0K
Feb 18, 2026 Buy	Stock Option (Right to Buy) A-Award	Auerbach Alan H President And CEO	CEO / President	227 474 Value: $1.52M
Feb 18, 2026 Buy	Common Stock A-Award	Auerbach Alan H President And CEO	CEO / President	159 778 Value: $1.07M
Feb 18, 2026 Buy	Common Stock A-Award	Nougues Maximo F Chief Financial Officer	C-Suite Officer	46 739 Value: $312.2K
Jan 07, 2026 Sell	Common Stock S-Sale	Nougues Maximo F Chief Financial Officer	C-Suite Officer	6 405 Value: $37.7K
Jan 07, 2026 Sell	Common Stock S-Sale	Auerbach Alan H President And CEO	CEO / President	18 012 Value: $105.9K
Jan 07, 2026 Sell	Common Stock S-Sale	Hunt Douglas M See Remarks	Officer	5 014 Value: $29.5K
Jan 06, 2026 Sell	Common Stock S-Sale	Nougues Maximo F Chief Financial Officer	C-Suite Officer	4 540 Value: $26.5K
Jan 06, 2026 Sell	Common Stock S-Sale	Auerbach Alan H President And CEO	CEO / President	16 938 Value: $99.0K
Jan 06, 2026 Sell	Common Stock S-Sale	Hunt Douglas M See Remarks	Officer	3 973 Value: $23.2K
Nov 11, 2025 Sell	Common Stock S-Sale	Miller Michael Patrick Director	Director	20 000 Value: $97.2K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT PUMA BIOTECHNOLOGY INC

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advance...

Read Full Profile Here